Gilead Sciences Inc.

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U… Ended
  2023-504194-21-00 Phase III 10 countries CARBOPLATIN; GEMCITABINE; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; PEMBROLIZUMAB; S…
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended
  2023-504195-14-00 Phase III 12 countries CARBOPLATIN; GEMCITABINE; PACLITAXEL; PACLITAXEL ALBUMIN-BOUND; SACITUZUMAB GOVI…
• A Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors Ended
  2024-513611-28-00 Phase II 3 countries SACITUZUMAB GOVITECAN
• A Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Ca… Ended
  2024-513225-23-00 Phase II 4 countries CARBOPLATIN; CISPLATIN; PEMBROLIZUMAB; SACITUZUMAB GOVITECAN
• A study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). Ended
  2024-512148-50-00 Phase III 10 countries DOCETAXEL; SACITUZUMAB GOVITECAN
• A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis Ended
  2024-511753-22-00 Phase III 12 countries SELADELPAR
• Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Expos… Ended
  2022-501763-40-00 Phase III 7 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE
• Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection Halted
  2023-506143-42-00 Phase II 1 country TENOFOVIR ALAFENAMIDE
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 Phase II/III 5 countries EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR; GS-1720; GS-4182
• N/A Ended
  2024-513121-22-00 Phase II 3 countries CARBOPLATIN; DOMVANALIMAB; PACLITAXEL; ZIMBERELIMAB
• Study in Participants With Normal Kidney Function and Reduced Kidney Function to Test How Kidney Function Can Change What Happens to Obeldes… Ended
  2023-504780-17-00 Phase I (Other) 1 country GS-5245
• Study of B/F/TAF in Participants Switching from CAB + RPV to B/F/TAF for HIV-1 Infection. Ended
  2023-506660-13-00 Phase IV 1 country EMTRICITABINE, TENOFOVIR ALAFENAMIDE, BICTEGRAVIR
• Study of GS-5718 in Participants With Cutaneous Lupus Erythematosus (CLE) Ended
  2022-501523-24-00 Phase II 3 countries GS-5718-03
• Study of GS-4528 for Adults With Solid Tumors Ended
  2022-502070-16-00 Phase I 1 country
• A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus … Ended
  2022-500177-13-00 Phase II 5 countries BEVACIZUMAB; CALCIUM LEVOFOLINATE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN HYDROC…
• A Registry Study of Treatment With Bulevirtide in Participants With Chronic Hepatitis D Infection Ended
  2022-501901-10-00 Phase IV 7 countries BULEVIRTIDE
• A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Local… Ended
  2024-513870-23-00 Phase III 8 countries DOCETAXEL; PACLITAXEL; SACITUZUMAB GOVITECAN; VINFLUNINE
• Study of Sacituzumab Govitecan’s Long-Term Safety in Subjects with Metastatic Solid Tumors Ended
  2023-505336-34-00 Phase IV 3 countries SACITUZUMAB GOVITECAN
• N/A Ended
  2024-517526-26-00 Phase III 1 country TENOFOVIR DISOPROXIL
• Study of Obeldesivir in Children and Adolescents With COVID-19 Ended
  2023-503282-27-00 Phase II/III 5 countries GS-5245

Showing 25–44 of 44 trials